處方藥市場：現狀分析與預測（2022-2028）

全球範圍內心血管疾病、高血壓和糖尿病等慢性病患病率的不斷上升正在推動處方藥市場的增長。 例如，疾病控制中心在2022 年報告稱，生活在美國的大約2,010 萬名成年人(7.2%) 患有某種形式的冠狀動脈疾病(CAD)，根據上面列出的來源，大約805,000 名生活在美國的成年人患有某種形式的冠狀動脈疾病(CAD)。美國會心髒病發作，其中605,000人會首次心髒病發作，200,000人以前有過心髒病發作，大約五分之一的心髒病發作是無聲的發作。 此外，用於治療 CAD 的藥物要麼是短期服用，要麼是終生服用。 此外，如果沒有獲得許可的醫療保健專業人員的書面指示，則無法獲得這些藥物。 因此，全球慢性病患病率的不斷上升預計將在預測期內推動處方藥市場的增長。

根據產品類型，市場分為仿製藥、品牌藥、孤兒藥等。 其中，仿製藥領域預計2021年市場複合年增長率較大。 這是由於原研藥的專利到期和隨後的監管批准。 與品牌藥相比，仿製藥的生產成本相對較低。 這使仿製藥公司有機會為消費者提供負擔得起的替代品。

市場按治療領域分為癌症、抗糖尿病、疫苗、感覺器官、免疫抑製劑、抗凝劑等。 其中，預計2021年免疫抑製劑領域的市場複合年增長率將大幅增長。 這是由於自身免疫性疾病的患病率不斷增加以及全球器官移植手術數量的增加。

根據分銷渠道，市場分為醫院藥房、零售藥房和網上藥房。 其中，預計酒店藥房市場在預測期內將以顯著的複合年增長率增長。 這是因為患者更喜歡從醫院購買藥品。 此外，服務態度好的醫院藥房購買藥品也可靠、安全，不會購買來源不可靠的假冒品牌藥品。 此外，住院患者從醫院購買藥品也很方便。 因此，上述因素預計將推動該領域的市場增長。

為了更好地了解處方藥行業的市場介紹，市場有北美（美國、加拿大、北美其他地區）、歐洲（英國、德國、法國、意大利、西班牙、歐洲其他地區）、亞洲太平洋地區（中國、日本、印度、韓國等亞太地區）以及世界其他地區。 預計亞太地區在預測期內將以顯著的複合年增長率增長。 這主要是由於該地區仿製藥製造商的增加、慢性病患病率的上升以及醫療保健支出的增加，所有這些都推動了處方藥的需求。

目錄

第一章市場介紹

• 市場定義
• 主要目的
• 利益相關者
• 限制

第二章研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章新型冠狀病毒感染（COVID-19）對全球處方藥市場的影響

第 6 章 2020-2028 年全球處方藥市場收入

第 7 章按產品類型劃分的市場洞察

• 通用
• 孤兒
• 其他

第 8 章按治療領域劃分的市場洞察

• 腫瘤學
• 抗糖尿病藥物
• 疫苗
• 感覺器官
• 免疫抑製劑
• 抗凝劑
• 其他

第 9 章按分銷渠道劃分的市場洞察

• 醫院藥房
• 零售藥店
• 網上藥店

第 10 章按地區劃分的市場洞察

• 北美市場
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲市場
  • 英國
  • 德國
  • 法國
  • 意大利
  • 西班牙
  • 其他歐洲地區
• 亞太市場
  • 中國
  • 日本
  • 印度
  • 韓國
  • 亞太地區的其他國家/地區
• 世界其他地區的市場

第11章處方藥市場動態

• 市場驅動因素
• 市場挑戰
• 影響分析

第 12 章處方藥市場機會

第13章處方藥市場趨勢

第14章需求側和供給側分析

• 需求方分析
• 供給側分析

第 15 章戰略洞察

第16章競爭場景

• 競爭狀況
  • 波特五力分析

第17章公司簡介

• F. Hoffmann-La Roche Ltd
• Teva Pharmaceuticals USA, Inc.
• sanofi-aventis U.S. LLC
• Pfizer Inc.
• GSK plc
• Novartis AG
• Merck & Co., Inc.,
• AbbVie Inc.
• AstraZeneca
• Johnson & Johnson Services, Inc.

第18章 免責事項

Prescription Drugs are the types of medication that can only be available to the patient only against the written instruction from the licenced healthcare professional. It includes information about the medication, how to be consumed, duration of treatment and frequency of the medication to be taken.

The increase in the prevalence of chronic diseases such as cardiovascular diseases, hypertension and diabetes across the globe is driving the market growth of prescription medicine. For instance, the Centre for disease control 2022, reports, around 20.1 (7.2%) million adults living in the United States have some type of coronary artery disease (CAD), further as per the above-mentioned source approximately 805,000 people living in the United States have heart attacks, of these 605,000 have a first heart attack, 200,000 are those people who already have had a heart attack and about 1 in 5 heart attack are silent ie, the damage is done and the person is unaware. Additionally, the medication taken for the treatment of CAD is either consumed for a short duration or lifelong. Furthermore, these medications are only be obtained against written instruction from a licenced healthcare professional. Hence, the growing prevalence of chronic disease across the globe is anticipated to boost market growth for prescription medicine in the forecasted period.

Based on product type, the market is segmented into generics, branded, orphans and others. Amongst these, the generic drug segment is anticipated to grow with a significant CAGR in the 2021 market. This is attributed to the patent expiration of the branded drugs coupled with their subsequent approval by the regulatory authority. Generic drugs are produced comparatively at low cost contrary to branded drugs. This creates an opportunity for generic companies to offer affordable alternatives to consumers.

Based on the therapeutic area the market is segmented into oncology, anti-diabetic, vaccines, sensory organs, immunosuppressants, anti-coagulants and others. Amongst these, the immunosuppressant segment is anticipated to grow with a significant CAGR in the 2021 market. This is attributed to the growing prevalence of autoimmune diseases and the rise in organ transplantation procedures globally. For instance according to the Global Observatory Donation and Transplant (GODT) report, 2021 the no. of organs transplanted increased from 1,44,302 in 2021 to 1,29,680 in 2020. This accounted for 11.3% in 2021 from 2020. Additionally, these medication helps to suppress the immunity and further prevents the organ rejection response of the body. Thus, with the rising prevalence of autoimmune diseases and increase in incidences of organ transplantation procedure is driving the market growth during the forecasted period.

Based on the distribution channel the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Amongst these the hospital pharmacies segment is anticipated to grow with a significant CAGR during the forecasted period. This is due to patients' preference for purchasing medicine from hospitals. Furthermore, hospital pharmacy source is reliable and safe for drug purchase, as it eliminates the purchase of misbranded drug purchased from non-reliable sources. Moreover, for inpatients, purchasing drugs from hospital pharmacies is easily accessible. Thus, the above-mentioned factors are anticipated to ful the market growth of this segment.

For a better understanding of the market adoption of the Prescription Drugs industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (UK, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Rest of World. Asia-pacific is anticipated to grow with a significant CAGR during the forecasted period. This is primarily driven by the increase in generic drug manufacturers, rising prevalence of chronic diseases and the increase in healthcare expenditure in this region is propelling the demand for prescription drugs.

Some of the major players operating in the market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceuticals USA, Inc., Sanofi-aventis U.S. LLC, Pfizer Inc., GSK plc, Novartis AG, Merck & Co., Inc., AbbVie Inc. , AstraZeneca, Johnson & Johnson Services, Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Prescription Drugs Market
• 2.2. Research Methodology of the Prescription Drugs Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL PRESCRIPTION DRUGS MARKET COVID-19 IMPACT

6 GLOBAL PRESCRIPTION DRUGS MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Generic
• 7.2. Orphan
• 7.3. Others

8 MARKET INSIGHTS BY THERAPEUTIC AREA

• 8.1. Oncology
• 8.2. Anti-Diabetic
• 8.3. Vaccines
• 8.4. Sensory Organs
• 8.5. Immunosuppressant's
• 8.6. Anti-Coagulant
• 8.7. Others

9 MARKET INSIGHT BY DISTRIBUTION CHANNEL

• 9.1 Hospital Pharmacies
• 9.2 Retail Pharmacies
• 9.3 Online Pharmacies

10 MARKET INSIGHTS BY REGION

• 10.1 North America Market
  • 10.1.1 U.S.
  • 10.1.2 Canada
  • 10.1.3 Rest of North America
• 10.2 Europe Market
  • 10.2.1 UK
  • 10.2.2 Germany
  • 10.2.3 France
  • 10.2.4 Italy
  • 10.2.5 Spain
  • 10.2.6 Rest of Europe
• 10.3 Asia-Pacific Market
  • 10.3.1 China
  • 10.3.2 Japan
  • 10.3.3 India
  • 10.3.4 South Korea
  • 10.3.5 Rest of APAC
• 10.4 Rest of the World Market

11 Prescription drugs MARKET DYNAMICS

• 11.1 Market Drivers
• 11.2 Market Challenges
• 11.3 Impact Analysis

12 PRESCRIPTION DRUGS MARKET OPPORTUNITIES

13 PRESCRIPTION DRUGS MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1 Demand Side Analysis
• 14.2 Supply Side Analysis

15 STRATEGIC INSIGHTS

16 COMPETITIVE SCENARIO

• 16.1 Competitive Landscape
  • 16.1.1 Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1 F. Hoffmann-La Roche Ltd
• 17.2 Teva Pharmaceuticals USA, Inc.
• 17.3 sanofi-aventis U.S. LLC
• 17.4 Pfizer Inc.
• 17.5 GSK plc
• 17.6 Novartis AG
• 17.7 Merck & Co., Inc.,
• 17.8 AbbVie Inc.
• 17.9 AstraZeneca
• 17.10. Johnson & Johnson Services, Inc.

17 DISCLAIMER